Patient experience sub-study of a randomised UK multicentre Phase 2 trial of ASTX727 versus hydroxycarbamide/best supportive care in myelodysplastic (MDS)/myeloproliferative (MPN) overlap syndromes (AMMO)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Ashleigh Ward, Sally Taylor, Grant Punnett, Ramsay Devaraj, Chhaya Sankhalpara, Rebecca Record, Kiran Batta, Jennifer Byrne, Catherine Cargo, Onima Chowdhury, Dominic Culligan, Nicholas Cunningham, Steve Knapper, Austin Kulasekararaj, Srinivasan Narayanan, Manoj Raghavan, Rob Sellar, Daniel Wiseman, Janelle Yorke
Institutions: The Christie NHS Foundation Trust, University of Manchester, Cancer Research UK Clinical Trials Unit, University of Birmingham, Nottingham University Hospitals NHS Trust, St James's University Hospital, Churchill Hospital, University of Oxford, MRC Weatherall Institute of Molecular Medicine, Oxford University Hospitals NHS Trust, Aberdeen Royal Infirmary, Belfast City Hospital, Cardiff University, King's College London, King's College Hospital NHS Foundation Trust, King's College Hospital, University Hospital Southampton NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, University College London, Hong Kong Polytechnic University
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7108465009
Cites:
Cited by:
Related to: